Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV.
HIV-1 infection
SARS-CoV-2 infection
T cell immunity
immunity waning
mRNA vaccines
neutralizing antibodies
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
05
10
2023
revised:
14
11
2023
accepted:
16
11
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
epublish
Résumé
(1) Background: Waning of neutralizing and cell-mediated immune response after the primary vaccine cycle (PVC) and the first booster dose (BD) is of concern, especially for PLWH with a CD4 count ≤200 cells/mm
Identifiants
pubmed: 38140145
pii: vaccines11121739
doi: 10.3390/vaccines11121739
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : ricerca corrente linea 1 e 2
Organisme : SHARP JA
ID : 848096